Browse All

Current Filters

CLEAR FILTER x

TITLE

The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy

Author:Lair, Lindsey   Qureshi, Irfan   Bechtold, Clifford   Durham, Susan   Campbell, Daniel   Marin, Jackie   Coric, Vladimir   

Session Name:P2: Neuromuscular and Clinical Neurophysiology (EMG): Spinal Muscular Atrophy and Hereditary Neuropathies  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P2.008  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Biohaven Pharmaceuticals, Inc, New Haven , CT  

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects

Author:Sevinsky, Heather   Awsare, Bharat   Rozakis, Rachel   Gentile, Kimberly   Mydlow, Patricia   Ashbrenner, Eric   Ham, Rachel   Stock, David   Qureshi, Irfan   Coric, Vladimir   Bertz, Richard   

Session Name:P4: General Neurology: Neuroimmunology  

Topic:General Neurology  

Program Number:P4.012  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Allucent, Cary, NC  

Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders

Author:Qureshi, Irfan   Beiner, Melissa   Bertz, Richard   Kaplita, Stephen   Yang, Rong   Munivar, Azim   Stock, David   Wirtz, Victoria   Coric, Vladimir   

Session Name:P4: General Neurology: Neuroimmunology  

Topic:General Neurology  

Program Number:P4.013  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  

No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole

Author:Bertz, Richard   Rozakis, Rachel   Donohue, Mary   Sevinsky, Heather   Awsare, Bharat   Kaplita, Stephen   Hussey, Elizabeth   Qureshi, Irfan   Coric, Vladimir   

Session Name:P4: General Neurology: Neuroimmunology  

Topic:General Neurology  

Program Number:P4.014  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Allucent, Cary, NC  

Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults

Author:Awsare, Bharat   Lerner, Jason   Ashbrenner, Eric   Sevinsky, Heather   Bozik, Michael   Dworetzky, Steven   Donahue, Lia   Killingsworth, Randall   Francoeur, Bruno   Qureshi, Irfan   

Session Name:P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P8.007  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Syneos Health, Quebec, QC, Canada